ten23 health enriches the Basel life sciences cluster
Coutry of origin
ten23 health supports global biotech and pharmaceutical customers in the development, manufacture and testing of injectable biopharmaceutical drugs.
In April 2021, Hanns-Christian Mahler and his partners founded ten23 health in Basel. The company develops drugs for its customers in the biotech and pharmaceutical industries. The company found ideal starting conditions at the Rosental site: it moved into around 4000 square meters of laboratory and office space for up to 150 employees on seven floors. By the end of October 2021, ten23 health had already acquired the company Swissfillon in Visp in the canton of Valais. Swissfillon is a leader in the sterile filling of complex pharmaceuticals into innovative containers and devices. By the end of 2021, ten23 health in Basel and Swissfillon in Visp were already employing around 90 people.
Knowing about the unmet need for the development and manufacture of increasingly complex drugs, Mahler founded ten23 health with this issue in mind: “The number and complexity of new molecules and new therapeutic approaches is increasing. Medical research faces growing challenges in terms of stability, usability and consistent manufacturing.” ten23 health supports its customers from product development planning to minimizing risks and manufacturing the drug.
At the Rosental site, the new company also benefits from the immediate neighborhood. These include medical services and the fire department, as well as companies that assist with laboratory infrastructure. “We also greatly appreciate the cooperation with the canton of Basel-Stadt,” Hanns-Christian Mahler states.
ten23 health focuses on “fairstainability”
For Hanns-Christian Mahler, CEO stands for Chief Enablement Officer. He leads the company with the goal that it should have a positive impact on society. Ten23 health puts patients, people and the planet at the center of all decisions and actions. Decisions are made in the spirit of “fairstainability” – fairness and sustainability. “As a company, we strive to leave the world in a better state than it would be without us,” Mahler says. Implementing this mindset in the company’s day-to-day operations is, of course, a challenge: “It means thinking about everything we do as a company and what our suppliers do and what is done with our services and products.”
This attitude also seems to be a strong argument when recruiting employees: “We see a brisk influx of applicants who are motivated to work in a company where they can and should have a strong influence on the organizational structure and culture.”
”We were able to take over a fully functional laboratory and office building in Basel and have found ideal starting conditions here. Several biotech and pharmaceutical companies, and thus potential new partners and customers, are based in the Basel Area. The region is dynamic and international, and therefore a promising starting point for attracting well-trained international specialists and building up our global business.Hanns-Christian MahlerCEO ten23 health